Product Overview
[Drug Name]
Generic Name: Itopride Hydrochloride Tablets
Trade Name: WeiBiLi Itopride Hydrochloride Tablets 50mg*12 Tablets
Pinyin Full Code: WeiBiLi YanSuanYiTuoBiLi Tablets 50mg*12 Tablets
[Main Ingredient]
The main ingredient of this product is itopride hydrochloride.
[Properties]
This product is a white film-coated tablet that appears white after removal of the coating.
[Indications/Main Functions]
This product is indicated for the treatment of indigestion symptoms caused by decreased gastrointestinal motility, including upper abdominal fullness, upper abdominal pain, loss of appetite, nausea, and vomiting, such as functional dyspepsia and chronic gastritis.
[Specifications]
50mg*12 tablets
[Dosage and Administration]
The recommended adult dose is 150mg daily, taken three times before meals. The dosage may be increased or decreased based on age and condition. The course of treatment is up to 8 weeks. (See the package insert for specific instructions.)
[Adverse Reactions]
Allergic reactions: Rarely occur rash, flushing, and itching (<0.1%), requiring discontinuation of the drug. Gastrointestinal: Diarrhea, constipation, abdominal pain, and increased salivation may occur occasionally (0.1-<5%). Psychiatric: Occasionally, dizziness, irritability, headache, sleep changes, and vertigo may occur; tremor has rarely been reported. Endocrine: Prolactin elevation may occur occasionally. If abnormalities such as galactorrhea or gynecomastia occur, appropriate measures such as suspension or discontinuation of treatment are necessary. Hematological: Leukopenia may occur occasionally. Monitoring complete blood counts is recommended, and if leukopenia occurs, discontinue the drug. Hepatic: Elevations in GOT, GPT, g-GTP, and ALP may occur rarely. Renal: Elevations in BUN and serum creatinine may occur occasionally. Other: Chest and back pain and fatigue may occur occasionally.
[Contraindications]
This product is contraindicated in patients with a known hypersensitivity to itopride hydrochloride or any of its ingredients. This product should not be used in patients with conditions where increased gastrointestinal motility could have a deleterious effect, such as gastrointestinal bleeding, mechanical intestinal obstruction, or perforation.
[Drug Interactions]
This product is primarily metabolized by flavin monooxygenase in the liver and does not interact with drugs metabolized by cytochrome P450. No changes in plasma protein binding were observed with co-administration of warfarin, diazepam, diclofenac sodium, ticlopidine hydrochloride, nifedipine, and nicardipine hydrochloride. Anticholinergics may reduce the efficacy of itopride hydrochloride, but anti-ulcer drugs such as cimetidine, ranitidine, teprenone, or cetraxate do not affect the prokinetic effect of itopride.
[Precautions]
1. This product can enhance the effects of acetylcholine, so caution should be exercised during use.
2. If this product is ineffective, avoid long-term, unintended use. Please read the instructions carefully and use as directed by your doctor.
[Pediatric Use]
Safety data for this product in children have not been established; its use should be avoided.
[Use in Elderly Patients]
Due to decreased physiological function in the elderly, adverse reactions are more common. Therefore, elderly patients should be carefully observed after taking this product. If adverse reactions occur, measures such as dosage reduction or discontinuation should be taken.
[Overdose]
Currently, there have been no reports of overdose with this product. In the event of an overdose, symptomatic treatment should be initiated.
[Pharmacology and Toxicology]
This product has dual effects of dopamine D2 receptor blockade and acetylcholinesterase inhibition. By stimulating the release of endogenous acetylcholine and inhibiting its hydrolysis, it enhances gastric and duodenal motility, promotes gastric evacuation, and has a moderate emetic effect.
